Merck & Co.(MRK)

RAHWAY, NJPharmaceutical4 H-1B visas (FY2023)

Focus: Merck & Co. is a diversified Big Pharma leader with $60.1B in FY2025 revenue, competing globally across oncology, vaccines, infectious disease, cardiovascular, and immunology. The company operates 69,000 employees and maintains significant R&D infrastructure with 51% R&D intensity.

Oncology Vaccines Infectious Disease Cardiovascular

Profile data last refreshed 5h ago · AI intelligence enriched 1w ago

Funding Stage

PUBLIC

Employees

69,000

Open Jobs

793+236 this month

Hot — 1709 jobs added in 30d

Net +236 (1709 new, 1473 removed). Aggressive expansion phase.

3 recent layoff filings (12 mo) — 496 affected

6/1/2026 — Rahway, NJ · 88 affected · Layoff
11/1/2025 — Rahway, NJ · 204 affected · Layoff
11/1/2025 — Rahway, NJ · 204 affected · Layoff

Source: state DOL filings via Big Local News

Should You Work at Merck & Co.?

AI assessment

Merck offers career stability and scientific depth in oncology/vaccines, but the patent cliff crisis and concurrent restructuring create near-term job security risk; best suited for candidates with 2+ year horizon or specialized expertise in growth areas.

Why Work Here

Strong R&D investment ($30.5B in FY2025) with active pipeline across oncology (pembrolizumab in Phase 3 gastric cancer, Phase 1/2 melanoma) and vaccines, offering deep scientific careers.

Data completeness

7/9 — Strong

Company HealthSolid

Pipeline

Early-stage

50 total

LOE Risk

9 imminent

BRIDION

Hiring

Stable

Revenue

$60.1B

FY2025

Key Products

JANUVIA

Type 2 diabetes mellitus

$4.1B

LOE Approaching

Help build intelligence for Merck & Co.

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Diversified therapeutic portfolio reducing single-product risk, with 602 active job openings and highest hiring in R&D (139 roles) and Commercial (133 roles) signaling growth areas.

100% H1B visa approval rate (4/4 in 2023) demonstrates commitment to global talent acquisition for specialized roles.

Watch Out For

Severe patent cliff exposure: $5.5B in revenue at risk by 2029, with JANUVIA (66% of revenue) losing exclusivity May 2027—triggering 554 documented layoffs across 2024–2026.
Organizational instability evident from 9 WARN Act filings (2024–2026) affecting 1,117 employees primarily at Rahway, NJ headquarters, with largest hit (310 employees, April 2024) cited as 'operational efficiency.'

Generated by Claude from Merck & Co.'s SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Merck's blockbuster and revenue anchor, but patent expires May 2027 creating existential portfolio pressure.

JANUMET

Type 2 diabetes mellitus

$799M

LOE Approaching2.4yr

Combination therapy losing exclusivity January 2029; contributes ~1.3% of revenue but demonstrates reliance on single therapeutic class.

JANUMET XR

Type 2 diabetes mellitus

$392M

LOE Approaching0.7yr

Extended-release formulation losing exclusivity May 2027; represents portfolio diversification attempt within same class.

BELSOMRA

Insomnia (orexin receptor antagonist)

$161M

Peak6.7yr

Peak-phase asset with 7+ years of exclusivity remaining; provides stability amid diabetes portfolio erosion.

LOSARTAN POTASSIUM

Hypertension

$143M

Post-LOE

Off-patent generic cardiovascular agent generating stable but non-growth revenue.

ISENTRESS

HIV-1 infection

$131M

Peak3.1yr

Integrase inhibitor in peak phase with September 2029 LOE; infectious disease franchise anchor.

DIFICID

Clostridioides difficile infection

$127M

LOE Approaching1.4yr

Specialty antibiotic facing January 2028 patent expiration; represents niche infectious disease play.

DULERA

Asthma

$117M

LOE Approaching

Combination inhaler in mature lifecycle; limited growth trajectory.

Pipeline & Clinical Trials

Streptococcus Pneumonia: Effects of PCV13 on Pneumococcal Carriage

Nasopharyngeal Carriage of S. Pneumoniae

N/A

Real time PCR

CMV

N/A

Functional Living Index - Emesis

Vomiting

N/A

non-interventional

Antiemetic Therapy

N/A

Clinical Trials (2)

NCT02921035Non-interventional Study to Assess Adherence to Treatment for Patients With RMS (MAIN-MS)

N/A

NCT01125475A Scandinavian Non-interventional Study of Adherence to RebiSmart Administered Rebif New Formulation (RNF) Treatment in Relapsing Remitting Multiple Sclerosis (RRMS) Subjects

HPV vaccine

Evaluating Attitudes Toward HPV Vaccinations in Pharmacies

N/A

Clinical Trials (3)

NCT02968420Long Term Immune Memory Responses to HPV Vaccination Following 2 vs 3 Doses of Quad-HPV Vaccine

Phase 4

NCT06915779Long Term Follow-up of HPV Vaccine in HIV (CTN 236)

Disease Management Assessment

Chemotherapy Induced Nausea and Vomiting

N/A

Post Pandemic Pneumococcal Carriage Among Children and Adults

Pneumococcal Carriage

N/A

Hanyang University Medical Center Arthritis Network

Arthritis, Rheumatoid

N/A

Individualized Feedback

HIV Prevention

N/A

Systematic Prevention of Further Fractures in Patients With Hip Fractures and Osteoporosis.

Hip Fracture

N/A

Indinavir sulfate

HIV Infections

N/A

Clinical Trials (1)

NCT00002410A Study of Three Different Anti-HIV Drug Combinations in HIV-Infected Patients

Phase 3

Subclinical Cytomegalovirus Reactivation in Acute ANCA-associated Vasculitis

ANCA Associated Vasculitis

N/A

easypod™

Growth Disorders

N/A

Clinical Trials (2)

NCT00738205Evaluation of Convenience and Compliance of the Easypod™ Electronic Self-injector

N/A

NCT01582334To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in Argentina

N/A

A Prospective, Longitudinal Study of Endothelial Function in HIV/HCV Coinfected Subjects

HIV

N/A

Relationship Between CETP Deficiency and Atherosclerosis in Patients With Hyperalphalipoproteinemia

Low CETP Activity

N/A

The Hyfrecator ® 2000 Electrosurgical System

Anal Dysplasia

N/A

Cancer care delivery

Care Delivery

N/A

ROTATEQ™ Post-Marketing Surveillance in the Philippines

Rotavirus Infections

N/A

Microbiology and Clinical Outcome of Pneumonia

Pneumonia

N/A

ERCP

Secondary Cholangitis

N/A

Vaccine Confidence Study Among Historically Marginalized Racial and Ethnic Groups

Vaccine Hesitancy

N/A

GARDASIL™ Post Marketing Surveillance in the Philippines (V501-077)

Papillomavirus Infections

N/A

Non Standard of Care blood samples collection

Haemato-oncological Paediatric Patients Under Intensive Chemotherapy

N/A

Message X Onsite/Offsite Vaccination

Human Papilloma Virus, Male

N/A

VARIVAX™

Varicella

N/A

Biopsy

Pruritus

N/A

Clinical Trials (1)

NCT05405686Effect of LH Supplementation on the Endometrial Gene Expression Profile in Poor Ovarian Responders

Phase 4

Screening and Brief Intervention

Medication Adherence

N/A

Gardasil

Genital Human Papilloma Virus Infection

N/A

quadrivalent human papillomavirus vaccine

Quadrivalent HPV Vaccine

N/A

Prevalence, Persistence, and Risk Factors for Oral Human Papillomavirus (HPV) Infections in College

Human Papillomavirus

N/A

Long Term Follow up Study of Predictive Markers in GHD and TS Children

Growth Hormon Deficiency

N/A

Clinical Trials (1)

NCT00699855Long Term Follow up Study of Predictive Markers in GHD and TS Children

N/A

Track bleeding patterns before and after implant

Contraception

N/A

PREMIUM, Observational Study

First Line WT KRAS mCRC

N/A

Clinical Trials (1)

NCT01756625PREMIUM, Observational Study

N/A

Retrospective Evaluation of Patient Failure to Follow-up at a Community Based Headache Clinic

Headache

N/A

Clinical Outcomes and Cost of Gram Negative Bacteremia

Gram-negative Bacteremia

N/A

ARQ 092

Proteus Syndrome

N/A

Surveillance of Non-invasive Streptococcus Pneumoniae Infections in Belgium

Pneumonia

N/A

Lipid Profile and Diabetes Mellitus in People With HIV

HIV Infections

N/A

Clinical Trials (1)

NCT04125784Lipid Profile and Diabetes Mellitus in People With HIV

N/A

Questionnaire

Lifestyle Factors

N/A

Clinical Trials (2)

NCT01141751An Observational Study Comparing Multiple Sclerosis International Quality of Life Questionnaire (MusiQoL) and Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) in Relapsing Multiple Sclerosis (RMS) Patients on Long-term Rebif® Therapy

N/A

NCT02072564Influence of Diet and Lifestyle Factors on the Results of the IVF

SARS-CoV-2 Antibody Analysis

Coronavirus Infection

N/A

Pre-Test Intervention

Cancer

N/A

MMR vaccine

Measles

N/A

Lipid Management in Clinical Practice (MK-0524A-115)

Lipid Metabolism Disorder

N/A

Vancomycin-Associated Nephrotoxicity

Nephrotoxicity

N/A

Clinical Trials (1)

NCT01216540Vancomycin-Associated Nephrotoxicity

N/A

Tetanus & Diphtheria booster vaccine

Vaccine Response Impaired

N/A

Recombinant-follicle stimulating hormone

Multifollicular Stimulation

N/A

Clinical Trials (1)

NCT01080729An Observational Study to Compare the Dose of Gonal-fTM FbM Prescribed by the Doctor With the Recommendation of the Dose Calculator Consort and to Evaluate the Ease of Use of Pre-filled Pen of Gonal-fTM FbM Pen

N/A

Pneumococcal Nasopharyngeal and Oropharyngeal Carriage in Adults

Preference, Patient

N/A

The Study of Gut Associated Lymphocytes in HIV and HCV/HIV Co-infected Patients

HIV

N/A

Colon resection

Diverticulitis

N/A

neuromuscular transmission monitoring

Postoperative Residual Curarisation

N/A

Interview Prep Quick Facts

Portfolio: 491 approved products, 114 clinical trials

Top TAs: Oncology, Neurology, Immunology

H-1B (2023): 4 approvals

Publications: 194 in PubMed

SEC Filings: 2 available

Open Roles: 793 active jobs

Portfolio Health

Pre-Launch69 (14%)

Launch3 (1%)

Growth2 (0%)

Peak35 (7%)

LOE Approaching232 (47%)

Post-LOE150

Therapeutic Area Focus

Oncology

122 marketed238 pipeline

Neurology

113 marketed81 pipeline

Immunology

115 marketed32 pipeline

Respiratory

102 marketed17 pipeline

Financials (FY2025)

Revenue

$60.1B1%

R&D Spend

$30.5B(51%)125%

Net Income

$365M

Hiring Trend

Actively Hiring

793

Open Roles

+479

Added

-422

Filled/Removed

Based on last 4 crawl cycles

Visa Sponsorship

Sponsors Work Visas

H-1B Petitions (FY2023)

Approved

Denied

100%

Rate

Source: USCIS H-1B Employer Data Hub

Risk Signals

WARN Act Layoff Notices (9)

2026-06

88 employees affected— Rahway, NJ

2025-11

204 employees affected— Rahway, NJ

2025-11

204 employees affected— Rahway, NJ

2025-08

58 employees affected— Rahway, NJ

Research Publications(10)

Recent peer-reviewed publications with author affiliations at this company

Impact of a 21-valent pneumococcal conjugate vaccine on pneumococcal disease incidence among adults 65-84 years of age in Belgium: An epidemiological modeling study.

Human vaccines & immunotherapeutics

2026

PMID:41860579

Disease burden and unmet needs in adults with neurofibromatosis type 1 and plexiform neurofibromas: A systematic literature review.

2007

$799M Part D

LOE: 2029

2011

$127M Part D

LOE: 2028 (18mo)

CLINICAL PHARMACOLOGY The primary action of beta-adrenergic agonist drugs, including albuterol, is to stimulate adenyl cyclase, the enzyme which catalyzes the formation of cyclic-3',5'- adenosine monophosphate (cyclic AMP) from adenosine triphosphate (ATP) in beta-adrenergic cells. The cyclic AMP thus formed mediates the cellular responses. Increased cyclic AMP levels are associated with relaxation of bronchial smooth muscle and inhibition of release of mediators of immediate hypersensitivity from cells, especially from mast cells. In vitro studies and in vivo pharmacologic studies have demonstrated that albuterol has a preferential effect on beta 2 -adrenergic receptors compared with isoproterenol. While it is recognized that beta 2 -adrenergic receptors are the predominant receptors in bronchial smooth muscle, data indicate that there is a population of beta 2 -receptors in the human heart existing in a concentration between 10% and 50%. The precise function of these receptors has not been established (see ). In controlled clinical trials, albuterol has been shown to have more effect on the respiratory tract, in the form of bronchial smooth muscle relaxation, than isoproterenol at comparable doses while producing fewer cardiovascular effects. Controlled clinical studies and other clinical experience have shown that inhaled albuterol, like other beta-adrenergic agonist drugs, can produce a significant cardiovascular effect in some patients, as measured by pulse rate, blood pressure, symptoms, and/or ECG changes. Albuterol is longer acting than isoproterenol in most patients by any route of administration because it is not a substrate for the cellular uptake processes for catecholamines nor for catechol- O -methyl transferase. Preclinical Intravenous studies in rats with albuterol sulfate have demonstrated that albuterol crosses the blood-brain barrier and reaches brain concentrations amounting to approximately 5% of the plasma concentrations. In structures outside the blood-brain barrier (pineal and pituitary glands), albuterol concentrations were found to be 100 times those in the whole brain. Studies in laboratory animals (minipigs, rodents, and dogs) have demonstrated the occurrence of cardiac arrhythmias and sudden death (with histologic evidence of myocardial necrosis) when beta-agonists and methylxanthines are administered concurrently. The clinical significance of these findings is unknown. Pharmacokinetics Albuterol is rapidly and well absorbed following oral administration. In studies involving normal volunteers, the mean steady-state peak and trough plasma levels of albuterol were 6.7 and 3.8 ng/mL, respectively, following dosing with a 2 mg albuterol tablet every 6 hours and 14.8 and 8.6 ng/mL, respectively following dosing with a 4 mg albuterol tablet every 6 hours. Maximum albuterol plasma levels are usually obtained between 2 and 3 hours after dosing, and the elimination half-life is 5 to 6 hours. These data indicate that albuterol

NCT02937155In the Era of the HPV Vaccine, What Are The Current HPV Subtypes Contributing to High Grade Cervical Dysplasia, Adenocarcinoma in Situ, and Early Cervical Cancer?

N/A

79 marketed35 pipeline

Cardiovascular

70 marketed32 pipeline

Hematology

71 marketed9 pipeline

Metabolic Diseases

38 marketed18 pipeline

58 employees affected— Rahway, NJ

2025-03

93 employees affected— Jersey City, NJ

2025-03

93 employees affected— Jersey City, NJ

2024-04

310 employees affected— Jersey City, NJ

2024-02

— Rahway, NJ

Source: state DOL filings, aggregated via Big Local News

1 active drug shortage

Merck filed 9 WARN Act notices (Feb 2024–Jun 2026) affecting at least 1,117 employees, with largest hit (310 workers, April 2024) at Jersey City cited as 'operational efficiency' and subsequent Rahway rounds (Feb 2024) labeled 'R&D restructuring.'

Persistent and large-scale layoffs concentrated at NJ headquarters indicate structural cost reduction tied to patent cliff crisis; career risk is elevated despite strong hiring signals in targeted areas.

Neuro-oncology advances

2026

PMID:41798680

Showing 5 of 10 publications

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Merck & Co.(MRK)

Should You Work at Merck & Co.?

Why Work Here

Key Products

Watch Out For

Products & Portfolio (72)

Key Products by Revenue

Other Products (37)

Pipeline & Clinical Trials

Recent News · Merck & Co.(10)

Open Jobs (793)

Senior Scientist, Clinical Research

Executive Director, Clinical Science, Oncology, Genitourinary, Melanoma, and Women’s Cancers

Executive Director, Clinical Science, Oncology, Thoracic, Lung, Head & Neck, and Gastrointestinal

Executive Director, Clinical Science, Oncology, Hematology, Oncology Assets and Early Development

Associate Director, R&D and Business Development Communications

Senior Clinical Director, Hematology

Senior Scientist, Pharmacokinetics

Associate Principal Scientist, Epidemiology

Specialist, Automation Engineering

Assoc. Dir , Strategic Forecasting

Associate Principal Scientist, Downstream Process Development

Executive Director, Program and Study Management, Immunology and Neurosciences

Executive Director, Program and Study Management, Cardiovascular/ Atherosclerosis, Respiratory & Metabolism

Executive Director, Program and Study Management, Infectious Diseases and Vaccines

Executive Director, Program and Study Management, Oncology

Senior Specialist, AI Innovation Consultant

Executive Director, Clinical Science, Cardiometabolic

Executive Director, Clinical Science, Immunology

Executive Director, Clinical Science, Infectious Disease & Vaccines

AVP, Head US Patient Engagement Center of Excellence

Associate Process Engineer, Technical Operations - Small Molecule Drug Substance

Biologics Process Research & Development, Associate Scientist

Biologics Process Research & Development , Senior Scientist

Product Manager- HR IT

Director, Pharmaceutical Analytical Sciences

Financials (FY2025)

Hiring Trend

Visa Sponsorship

Risk Signals

WARN Act Layoff Notices (9)

Research Publications(10)